Global Nuclear Medicine Market - Growth, Trends & Forecasts (2015-2020)
|出版商||Mordor Intelligence LLP||商品編碼||319327|
|全球核醫學市場:成長，趨勢，預測 Global Nuclear Medicine Market - Growth, Trends & Forecasts (2015-2020)|
|出版日期: 2016年01月01日||內容資訊: 英文||
The Global Nuclear medicine market has been estimated to be valued at USD 11.04 Billion for the year 2015 and the market is expected to hit USD 19.4 billion by the year 2020 at a CAGR of 12.3%. The market is set to be mostly driven by the therapeutic radio pharmaceuticals, which are expected to grow at CAGR of 30% during 2015 to 2020.
Though in existence since the 1940s the nuclear medicine market came to the forefront only in the past decade mostly due to the emergence of new radio nucleotides and the number of products under development has grown since then, at an increasing pace. Nuclear medicine has applications in the fields of cardiology, lymphoma, thyroid, neurology oncology, and others.
Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Increased public awareness and use of Radio diagnostic techniques such as SPECT and PET also fuel the market growth. Some of the major constrains for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.
The radiopharmaceutical market is broadly classified into two segments, namely diagnostic and therapeutic. Diagnostic radioisotope segment is sub-divided into SPECT isotopes (Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123) and Gallium) and PET radioisotopes (Fluorine-18, Rubidium-82 (RB-82)). Therapeutic radioisotopes segment is divided into Alpha emitters (Radium-223), Beta Emitters (Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (iodine-125, Cesium-131, Palladium-103, & Iridium-192). Diagnostic radioisotopes segment holds the largest share in Nuclear Medicine Radioisotopes Market
Based on geography, the market is segmented into North America, Europe and Asia-Pacific and Rest of the World. North America is the dominant market for diagnostic radioisotopes. Within North America, USA is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. Germany is the largest consumer market for radiopharmaceuticals in the Europe. India and China hold a potential market for radioisotope due to rising healthcare requirement both diagnostic and therapeutic leading to an increase in demand for different radioisotopes in various treatments and applications
Many players in this market are trying to expand their product portfolio in order to top the global market. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Some of the major players in the radiopharmaceuticals market are Covidien Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).